PowerUp extends Aspire merger disclosure schedule delivery to Oct 11, 2024

Aspire Biopharma Holdings, Inc.

Second Amendment Agreement moves Disclosure Schedule Delivery Date to October 11, 2024.
Allows additional time for due diligence and compilation of disclosure schedules.
No changes to merger consideration, equity incentive pool, or other key terms.
Amendment is in connection with the previously announced business combination with Aspire Biopharma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.